RESUMEN
A 75-year-old patient was evaluated for dementia. His past medical history included an ischaemic cardiomyopathy treated with aspirin daily. His neurological examination showed mild ataxia syndrome and central deafness. The neuropsychological examination did not suggest Alzheimer's disease. No specific aetiology was found from biological investigations, but MRI scans revealed a superficial siderosis, which was further confirmed with CSF exams. This case highlights the interest of MRI with echo-gradient-T2 weighted sequences in patients investigated for memory disorders. Once the diagnosis is known, specific preventive measures have to be taken: searching for a treatable source of bleeding and the interruption of antiplatelet aggregation or anticoagulant treatments.
Asunto(s)
Aspirina/efectos adversos , Demencia/etiología , Hemosiderosis/etiología , Inhibidores de Agregación Plaquetaria/efectos adversos , Hemorragia Subaracnoidea/inducido químicamente , Anciano , Demencia/diagnóstico , Demencia/psicología , Demencia/terapia , Hemosiderosis/complicaciones , Hemosiderosis/diagnóstico , Hemosiderosis/terapia , Humanos , Imagen por Resonancia Magnética , Masculino , Memoria , Pruebas Neuropsicológicas , Hemorragia Subaracnoidea/diagnóstico , Hemorragia Subaracnoidea/terapiaRESUMEN
Patients with essential thrombocythemia often complain of various subjective neurological symptoms. This prospective study aims to assess their incidence and response to therapy. Among 37 consecutive patients with essential thrombocythemia, 11 presented with neurological symptoms. Among them 4 had thrombotic events, 7 complained of transient or fluctuating subjective symptoms, and one had both. Brain magnetic resonance imagery failed to detect any substratum in patients with subjective symptoms. JAK2V617F mutation was found in 9 of 11 patients with neurological symptoms versus 14 of 26 patients without symptoms. Ten patients received low-dose aspirin for these symptoms: complete resolution was observed in 3, improvement with persisting episodes in 2, and resistance to aspirin in 2 patients, in whom addition of cytoreductive therapy became necessary to resolve those disabling symptoms. In this prospective cohort, 30% of patients with essential thrombocythemia presented neurological symptoms. Aspirin was fully efficient in only 30% of cases. JAK2V617F mutation could be a risk factor for such symptoms.